Fredun Pharmaceuticals Files SEBI SAST Disclosure For 40,000 Share Allotment
Fredun Pharmaceuticals submitted mandatory SEBI SAST regulatory disclosure following the conversion of warrants into 40,000 equity shares by promoter Mrs. Daulat Nariman Medhora. The filing reveals detailed shareholding changes, with the promoter group's total holdings adjusting to 45.54% and the company's paid-up capital increasing from ₹5,47,26,900 to ₹5,51,26,900.
*this image is generated using AI for illustrative purposes only.
Fredun Pharmaceuticals Limited has filed a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the allotment of 40,000 equity shares to its promoter group upon warrant conversion. The regulatory filing, submitted on April 13, 2026, provides detailed shareholding changes resulting from the warrant conversion completed on April 09, 2026.
SEBI SAST Disclosure Details
The disclosure filed with BSE Limited reveals comprehensive shareholding patterns of the promoter group before and after the warrant conversion. Company Secretary and Compliance Officer Vaishnavi Sahu submitted the mandatory filing, which shows the promoter group's total holding and voting rights.
| Parameter: | Before Acquisition | After Acquisition | Change |
|---|---|---|---|
| Shares with Voting Rights: | 24,17,053 | 24,57,053 | +40,000 |
| Voting Capital %: | 44.17% | 44.57% | +0.40% |
| Warrants/Convertible Securities: | 93,332 | 53,332 | -40,000 |
| Total Holdings %: | 45.88% | 45.54% | -0.34% |
| Diluted Share Capital %: | 42.43% | 42.42% | -0.01% |
Warrant Conversion Transaction
The allotment involved conversion of warrants into 40,000 equity shares by Mrs. Daulat Nariman Medhora, a promoter and Whole Time Director. The conversion was executed at ₹1,250 per share, with a face value of ₹10 each and premium of ₹1,240 per share.
| Transaction Details: | Specifications |
|---|---|
| Allottee: | Mrs. Daulat Nariman Medhora |
| DIN: | 01745277 |
| Shares Converted: | 40,000 |
| Conversion Price: | ₹1,250 per share |
| Total Transaction Value: | ₹5,00,00,000 |
| Mode of Acquisition: | Conversion of warrants into equity shares |
Share Capital Changes
The warrant conversion resulted in changes to the company's share capital structure. The paid-up capital increased from ₹5,47,26,900 to ₹5,51,26,900, while the diluted share capital stands at ₹5,91,76,220 after considering outstanding convertible securities.
Regulatory Compliance Framework
The disclosure was filed in accordance with SEBI (SAST) Regulations, 2011, which mandate reporting of substantial acquisitions and changes in shareholding patterns. The promoter group's acquisition through warrant conversion required disclosure as it involved changes in voting rights and shareholding percentages. The filing includes detailed calculations based on total share capital and diluted share capital, ensuring transparency in ownership structure changes.
The company maintains its listing on BSE Limited and continues to comply with all applicable disclosure requirements under SEBI regulations. The warrant conversion represents the completion of a preferential issue process that began with shareholder approvals in October 2025.
Historical Stock Returns for Fredun Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.41% | +18.03% | +25.69% | +32.25% | +205.12% | +384.35% |
Will the remaining 53,332 warrants held by the promoter group be converted in the near future, and how might this impact the shareholding structure?
What strategic initiatives or expansion plans might Fredun Pharmaceuticals pursue with the ₹5 crore raised from this warrant conversion?
Could this increased promoter stake signal preparation for potential delisting or acquisition discussions in the pharmaceutical sector?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
